Cragg David

SEC source: 0001061983-22-000067 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,233

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/07/2022 and does not represent a sale by the reporting person.

SEC source: 0001061983-22-000053 · edgardoc.xml · derivative · entry 4

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,138

Underlying: Common Stock · 46,138 shares

Expires 2032-03-01

F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

SEC source: 0001061983-22-000053 · edgardoc.xml · derivative · entry 3

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,862

Underlying: Common Stock · 3,862 shares

Expires 2032-03-01

F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

SEC source: 0001061983-22-000053 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,632

F2 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant.

SEC source: 0001061983-22-000053 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,632

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/02/2022 and does not represent a sale by the reporting person.

SEC source: 0001061983-22-000037 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,090

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2022 and does not represent a sale by the reporting person.

SEC source: 0001061983-22-000025 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,161

F2 · kind: Comprised of restricted stock units (RSUs) issued upon conversion of certain PSUs granted to the Reporting Person on May 11, 2021. The satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into RSUs of the Issuer. These RSUs will vest in whole on February 16, 2023.

SEC source: 0001061983-22-000025 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,036

F1 · kind: On or about May 11, 2021, the Reporting Person was granted performance-based stock units (PSUs) of the Issuer, which upon satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into fully-vested shares of common stock of the Issuer.

SEC source: 0001061983-21-000255 · edgardoc.xml · derivative · entry 6

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,519 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-21-000255 · edgardoc.xml · derivative · entry 5

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,481 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-21-000255 · edgardoc.xml · nonDerivative · entry 4

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,704

F1 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000255 · edgardoc.xml · nonDerivative · entry 3

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,185

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000255 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,704

F1 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000255 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000247 · edgardoc.xml · derivative · entry 6

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,675 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

SEC source: 0001061983-21-000247 · edgardoc.xml · derivative · entry 5

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,325 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

SEC source: 0001061983-21-000247 · edgardoc.xml · nonDerivative · entry 4

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,704

F1 · security: Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.

F2 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F3 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000247 · edgardoc.xml · nonDerivative · entry 3

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.

F2 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F3 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000247 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,704

F1 · security: Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.

F2 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F3 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000247 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.

F2 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F3 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000219 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,123

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000208 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,692

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000200 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,542

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000162 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,158

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000154 · edgardoc.xml · derivative · entry 6

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,562 shares

Expires 2022-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

SEC source: 0001061983-21-000154 · edgardoc.xml · derivative · entry 5

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,437 shares

Expires 2022-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

SEC source: 0001061983-21-000154 · edgardoc.xml · nonDerivative · entry 4

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,171

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000154 · edgardoc.xml · nonDerivative · entry 3

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,608

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000154 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,171

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000154 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · Chief HR & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2021.

F2 · balance_after: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000075 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,625

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/06/2021 and does not represent a sale by the reporting person.

F2 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000058 · edgardoc.xml · derivative · entry 3

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,879

Underlying: Common Stock · 34,879 shares

Expires 2031-03-01

F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

SEC source: 0001061983-21-000058 · edgardoc.xml · derivative · entry 2

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,121

Underlying: Common Stock · 10,121 shares

Expires 2031-03-01

F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

SEC source: 0001061983-21-000058 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,775

F1 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant.

F2 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000048 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,775

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/01/2021 and does not represent a sale by the reporting person.

F2 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-21-000040 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,850

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2021 and does not represent a sale by the reporting person.

F2 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 8

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,243 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 7

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,243

Underlying: Common Stock · 7,423 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 6

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,666

Underlying: Common Stock · 7,423 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Incentive stock options granted on 2/28/2011 to purchase 7,423 shares at an exercise price of $9.42 per share converted to non-qualified stock options to purchase 7,423 shares at an exercise price of $9.42 per share as a result of a modification to the original grant to permit a "net exercise" of the stock options. Conversion transaction is permitted pursuant to the Issuer's Amended and Restated 2004 Equity Incentive Plan and the prior resolution of the Issuer's Compensation and Talent Committee of the Board of Directors.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 5

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 7,423 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Incentive stock options granted on 2/28/2011 to purchase 7,423 shares at an exercise price of $9.42 per share converted to non-qualified stock options to purchase 7,423 shares at an exercise price of $9.42 per share as a result of a modification to the original grant to permit a "net exercise" of the stock options. Conversion transaction is permitted pursuant to the Issuer's Amended and Restated 2004 Equity Incentive Plan and the prior resolution of the Issuer's Compensation and Talent Committee of the Board of Directors.

F4 · balance_after: Number of derivative securities beneficially owned following reported transaction is zero (0). The 1 security that is reported is the result of rounding of shares attributable to Issuer?s reverse stock split that occurred on 6/25/2013.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 4

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,229

F2 · kind: Transaction represents a "net exercise" of 9,243 outstanding non-qualified stock options granted on 2/28/2011 and 7,423 outstanding non-qualified stock options that result from the conversion on 12/15/20 of incentive stock options granted on 2/28/2011. The Reporting Person received 6,013 shares of Common Stock on the net exercise of a stock options to purchase an aggregate of 16,666 shares of Common Stock, with a remaining payable by Reporting Person to the Issuer of $17.45. The Issuer withheld 10,653 shares of Common Stock underlying the stock options for payment of the exercise price and tax withholding using a stock price on 12/15/20 of $21.00. In addition to the withholding of 10,653 shares of Common Stock, the Reporting Person will pay $17.45 in cash to the Issuer for the remainder of his exercise price and tax liability.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 3

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,894

F2 · kind: Transaction represents a "net exercise" of 9,243 outstanding non-qualified stock options granted on 2/28/2011 and 7,423 outstanding non-qualified stock options that result from the conversion on 12/15/20 of incentive stock options granted on 2/28/2011. The Reporting Person received 6,013 shares of Common Stock on the net exercise of a stock options to purchase an aggregate of 16,666 shares of Common Stock, with a remaining payable by Reporting Person to the Issuer of $17.45. The Issuer withheld 10,653 shares of Common Stock underlying the stock options for payment of the exercise price and tax withholding using a stock price on 12/15/20 of $21.00. In addition to the withholding of 10,653 shares of Common Stock, the Reporting Person will pay $17.45 in cash to the Issuer for the remainder of his exercise price and tax liability.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,639

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000062 · edgardoc.xml · derivative · entry 3

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,408

Underlying: Common Stock · 50,408 shares

Expires 2030-03-05

F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

SEC source: 0001061983-20-000062 · edgardoc.xml · derivative · entry 2

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,592

Underlying: Common Stock · 9,592 shares

Expires 2030-03-05

F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

SEC source: 0001061983-20-000062 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,098

F1 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000051 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,098

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2020 and does not represent a sale by the reporting person.

F2 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000044 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,482

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person.

F2 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000036 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,632

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person.

F2 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.